CDP-Choline Reference

Plain English

What it is

CDP-choline (also called citicoline, and sold under the branded form Cognizin) is a substance the body uses as a choline source to make acetylcholine, a brain signaling chemical, and to build phosphatidylcholine, a component of cell membranes. In the United States it is sold as a dietary supplement, not as an FDA-approved drug. Several other countries treat it as a medicine.

What people use it for

In the nootropic community it is used as a choline source for focus, memory, and mental energy, and many people find it feels milder than alpha-GPC. Outside the US it is used as a prescribed medicine for cognitive impairment and stroke recovery, especially memory problems linked to poor blood flow in the brain.

What the science shows

Human research is real but mixed. Some studies and reviews report cognitive benefits, particularly for impairment of blood-flow (vascular) origin, while other large trials found no clear benefit and a stroke meta-analysis found it did not improve recovery. It is generally well tolerated, with digestive upset being the most common complaint.

The catch

In the US the cognitive claims are largely unproven and the supplement is not FDA-reviewed for treating any disease, so strength and contents can vary between products. Study results differ widely and some people may notice no benefit. For research and educational purposes only. Not medical advice.

Reference summary

Stroke-recovery trials and cognitive-impairment literature exist in non-US markets. Larger meta-analyses report mixed but generally positive effects.

Regulatory and posture

Categories

Nootropic, Cognitive

Aliases

Citicoline, Cognizin, Ceraxon

Evidence posture

human - Sold as a dietary supplement in the US, not as an FDA-approved drug. Approved in non-US markets for stroke / cognitive impairment.

Regulatory status

No FDA-approved citicoline drug label in the US. Approved in Japan, Italy, and many other non-US markets for stroke and cognitive impairment. Sold as a dietary supplement (Cognizin) in the US.

Content review status

research reference